ENTA 8.85 ▼ -0.45% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Enanta Pharmaceuticals In...

    NASDAQ: ENTA · Real-Time Price · USD
    8.85
    -0.04 (-0.45%)
    At close: Sep 05, 2025, 3:59 PM
    8.99
    1.58%
    After-hours: Sep 05, 2025, 06:35 PM EDT
    -0.45%
    Bid 7.8
    Market Cap 189.19M
    Revenue (ttm) 64.81M
    Net Income (ttm) -92.01M
    EPS (ttm) -4.34
    PE Ratio (ttm) -2.04
    Forward PE -2.92
    Analyst Buy
    Ask 9.44
    Volume 102,681
    Avg. Volume (20D) 175,459
    Open 8.96
    Previous Close 8.89
    Day's Range 8.72 - 9.05
    52-Week Range 4.09 - 13.37
    Beta 0.84

    About ENTA

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol ENTA
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for ENTA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Enanta Pharmaceuticals Inc. is scheduled to release its earnings on Nov 24, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 month ago
    +8.51%
    Enanta Pharmaceuticals shares are trading higher a... Unlock content with Pro Subscription
    3 months ago
    +14.31%
    Enanta Pharmaceuticals shares are trading higher after JMP Securities maintained an Outperform rating on the stock and raised its price target from $23 to $24.
    news image

    2 weeks ago · businesswire.com

    Enanta Pharmaceuticals to Participate in September Investor Conferences

    WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...

    news image

    2 weeks ago · businesswire.com

    Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union

    WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immuno...

    news image

    4 weeks ago · zacks.com

    Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates

    Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $1.25. This compares to a loss of $1.07 per share a year ago.

    news image

    4 weeks ago · businesswire.com

    Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025

    WATERTOWN, Mass.--(BUSINESS WIRE)-- #KIT--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunol...

    news image

    1 month ago · businesswire.com

    Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. “HCW@Home” Series

    WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...

    news image

    1 month ago · businesswire.com

    Enanta Pharmaceuticals to Participate in Baird's Biotech Discovery Series

    WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...

    news image

    2 months ago · businesswire.com

    Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus

    WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...

    Add to Watchlist